
Accepted Manuscript

Synthesis of (S)-3-Hydroxytetrahydropyran from L-glutamic Acid

Yang Geng, Maolin Zheng, Jingya Li, Dapeng Zou, Yusheng Wu, Yangjie Wu

PII: DOI:	S0040-4039(17)31115-2 http://dx.doi.org/10.1016/j.tetlet.2017.09.008
Reference:	TETL 49278
To appear in:	Tetrahedron Letters

Received Date:18 June 2017Revised Date:27 August 2017Accepted Date:4 September 2017




Please cite this article as: Geng, Y., Zheng, M., Li, J., Zou, D., Wu, Y., Wu, Y., Synthesis of (S)-3-Hydroxytetrahydropyran from L-glutamic Acid, *Tetrahedron Letters* (2017), doi: http://dx.doi.org/10.1016/j.tetlet. 2017.09.008

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Graphical Abstract

To create your abstract, type over the instructions in the template box below. Fonts or abstract dimensions should not be changed or altered.





Tetrahedron Letters

journal homepage: www.elsevier.com

Synthesis of (S)-3-Hydroxytetrahydropyran from L-glutamic Acid

Yang Geng,^a Maolin Zheng,^b Jingya Li,^b Dapeng Zou,^a* Yusheng Wu,^{a, b, c}* and Yangjie Wu^{a, b}* a The College of Chemistry and Molecular Engineering, Zhengzhou University, Zhengzhou 450052, People's Republic of China b Tetranov Biopharm, LLC. and Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou, 450052, People's Republic of China c Tetranov International, Inc. 100 Jersey Avenue, Suite A340, New Brunswick, NJ 08901, USA.

ARTICLE INFO

ABSTRACT

Article history: Received Received in revised form Accepted Available online A concise synthesis of (S)-3-hydroxytetrahydropyran from natural L-glutamic acid has been developed. The intramolecular etherification starting from 1, 5-diol was promoted by trifluoromethanesulfonic anhydride. The clinnamates of the alcohols were prepared for accurately determining the optical purity by HPLC method.

2016 Elsevier Ltd. All rights reserved.

1

Keywords:

(S)-3-hydroxytetrahydropyran Trifluoromethanesulfonic anhydride Intramolecular etherification

Introduction

As major components of the chiral drugs, the chiral organic molecules play an increasingly important role in pharmaceutical. The enantiomers of a chiral drug have shown different pharmacokinetic, pharmacodynamics and toxicological properties in human body.¹ The demand for chiral compounds is dramatically increasing accompany with the rapid growth of pharmaceutical research and development. This has brought prosperity in asymmetric synthesis² and resolution methodology.³ Preparing target chiral compounds from natural chiral materials, affords a facile and economic solution for chiral synthesis.

3-Hydroxytetrahydropyran forms an important substructure of some pharmacologically active compounds. These compounds seem to confer certain valuable properties on potential drugs. For examples, 3-hydroxytetrahydropyran containing compounds (**Figure 1**) are potential Soft ROCK inhibitor (**A**),⁴ glucokinase activator (**B**),⁵ Mnk2 kinases inhibitors (**C** and **D**),⁶ respectively.




Figure 1. 3-Hydroxytetrahydropyran containing drugs


The racemic 3-hydroxytetrahydropyran was firstly synthesized in the year of 1959 by Barker and co-workers.⁷ To date, various methods for the synthesis of racemic 3-hydroxytetrahydropyran

have been developed.⁸ Hydroboration-oxidation of 3, 4-dihydroafford dozens of grams of 2H-pyran can 3hydroxytetrahydropyran.9 However, the enantiomers of 3hydroxytetrahydropyran with high optical purity are not easily synthesized. So far, utilizing the asymmetric hydroborationoxidation of 3, 4-dihydro-2H-pyran with optically pure organoboranes as reductive agent has been the major way for preparing chiral 3-hydroxytetrahydropyran.¹⁰ In the 1980s, Brown and co-workers^{10a-f} made outstanding works in the preparation of high enantiomeric purity diisopinocampheylborane, and using them in asymmetric hydroboration of cyclic olefin, ketones and so on. Among them, the method^{10a} for the synthesis of (R)-3-hydroxytetrahydropyran was described as follows (Scheme 1): Hydroboration-oxidation of 3, 4-dihydropyran with (-)-diisopinocampheylborane gave the (R)-3-hydroxytetrahydropyran in 83% ee. 10b Treatment of the 3tetrahydropyrandiisopinocampheylborane with acetaldehyde provides the diethyl boronate. Then, iminodiacetic acid converts this boronate into a crystalline chelate. After recrystallizations twice from DMSO, the optical purity was up to 99% ee. Then, the crystalline chelate was acidification, followed by oxidation to give the crude product. The alcohol was distilled and purified by preparative GC to afford the (R)-3-hydroxytetrahydropyran in >99% ee. This method has some advantages for the synthesis of high optical purity 3-hydroxytetrahydropyran. However, the high optical purity diisopinocampheylborane was expensive and not stable to moisture. Besides Brown's method, Jacobsen and coworkers reported a synthesis of (S)-3-hydroxytetrahydropyran through a intramolecular kinetic resolution of epoxy alcohols catalyzed by a [CoIII(salen)] complex, and this method gave (S)-3-hydroxytetrahydropyran in 46% yield with 95% ee.¹¹

Using the chiral amino acids to prepare chiral pyran¹² and furan¹³ derivatives in kilograms scale have been reported with high optical purity. Herein, we report a protocol to prepare (S)-3-hydroxytetrahydropyran through intramolecular etherification of

Tetrahedron

1, 5-diol which can be transformed from available chiral starting material L-glutamic acid.




Scheme 1. Synthesis of 3-hydroxytetrahydropyran with high optical purity

Results and Discussion

In general, the process begins with the transformation of Lglutamic acid into a crucial intermediate (S)-2-(benzyloxy) pentane-1, 5-diol (**Table 1, compound 1**) which then undergoes cyclization and debenzylation to isolate the product (S)-3aminotetrahydrofuran.

At the outset of our studies, the (S)-2-(benzyloxy)pentane-1,5diol was prepared from L-glutamic acid according to the literature.^{14, 15} The benzyl was chosen as the protecting group because of its stability under LiAlH₄ reduction condition and easy removal under mild conditions. To go insight of the crucial intramolecular etherification, some common closed loop methods were tried. When 1, 5-diol was treated with 0.2 eq. ptoluenesulfonic acid (entry 1), refluxed in toluene for 18 h with the water diversion device, no product was detected. Mitsunobu cyclization (entry 2) was tried and afforded the cyclization product **2** in the low yield of 15%. Intramolecular nucleophilic substitution reaction (entry 3) also used for the cyclization, but the yield was also unsatisfactory.




1.0 eq. TFAA, 3.0 eq. Pyridine, DCM, 0-25 °C, 1 h

7	1.0 eq. Tf ₂ O, 5% DMAP, 3.0 eq. Et ₃ N, DCM, 25 °C, 1 h	48
6	1.0 eq. Tf2O, 3.0 eq. Et3N, DCM, 0–-25 °C, 3 h	40
5	1.0 eq. Tf ₂ O, 3.0 eq. Pyridine, DCM, 0 °C, 1 h	n.d.

^{*a*}Conditions: compound **1** (1 mmol). ^{*b*} The isolated yield was obtained via silica gel column. ^{*c*}n.d. = not detected by GC–MS.

Trifluoroacetic anhydride (entry 4) and trifluoromethanesulfonic anhydride (entry 5) were designed as dehydration agents with excess of pyridine as base, but only the esterification reaction was detected. To our delight, when 1, 5-


diol was treated with 1.0 eq. of trifluoromethanesulfonic anhydride, 3.0 eq. of triethylamine in dichloromethane at 0 °C to 25 °C for 3 h (entry 6), the compound **2** was isolated in 40% yield. Further investigation indicated that the addition of a catalytic amount of DMAP promoted the reaction and gave the compound **2** with 48% yield.



Reagents and conditions: (a) HCl (conc.), NaNO₂, H₂O, -5 °C, 16 h; HCl (conc.), MeOH, reflux, 12 h; BnBr, Ag₂O, EtOAc, rt, 48 h; 65% yield (3 steps). (b) LiAlH₄, Et₂O, 24 h, 85% yield; (c) Tf₂O, DMAP, Et₃N, CH₂Cl₂, 25 °C, 0.5 h, 49% yield; (d) Pd(OH)₂, H₂ (1 atm), MeOH, 40 °C, 20 h, 82% vield.

Scheme. 2 Preparation of grams of (S)-3hydroxytetrahydropyran.

Next, the grams scale of (S)-3-hydroxytetrahydropyran was prepared as shown in **Scheme 2**. Compound **1-1** was synthesized with yield of 65% in 3 steps from L-glutamic acid according to the literatures. Then compound **1-1** was treated with 2.0 eq. of LiAlH₄ in ether, and transformed into (S)-2-(benzyloxy)pentane-1, 5-diol in 85% yield.¹⁵ Treatment of 21.0 g of 1, 5-diol with the optimum conditions afforded the cyclization product **2** 9.4 g (49% yield). The benzyl protective group was removed using palladium hydroxide in MeOH at 40 °C under 1 atm H₂ to give the compound **3** with 85% yield. Determination of chiral purity of the product was achieved via chiral HPLC using the cinnamamide derivative¹¹ of the (S)-3-hydroxytetrahydropyran as illustrated in **Figure 2**. The results revealed that this method afforded the (S)-3-hydroxytetrahydropyran with high optical purity (> 95% ee) without other purification.



Regents and Conditions: (a) Cinnamyl chloride, DMAP, Et₃N, DCM. (b) HPLC conditions: Daicel AD-H column (4.6×250 mm, 5 μ m), mobile phase: *n*-heptane: i-PrOH = 0.9 : 0.03 (v/v); detector: UV, λ = 254 nm.

Figure 2. HPLC of cinnamamide derivatives.

Conclusion

n.d.

In summary, (S)-3-hydroxytetrahydropyran with grams scale was prepared from inexpensive natural chiral L-glutamic acid. The intramolecular etherification was promoted by trifluoromethanesulfonic anhydride in mild conditions. This facile method affords a convenient way for the synthesis of other similar chiral derivatives.

Acknowledgements

2

ACCEPTED MANUSCRIPT

We are grateful to the National Natural Science Foundation of China (21172200) for financial support

References and notes

- (1) Leek, H.; Andersson, S. Molecules 2017, 22, 158.
- (2) (a) Christmann, M.; Brase, S. Asymmetric Synthesis II: More Methods and Applications 2012. (b) Walsh, P.; Kozlowski, M. Fundamentals of Asymmetric Catalysis; University Science Books: Sausalito, CA, 2009.
- (3) Leek, H.; Thunberg, L.; Jonson, A. C.; Ohlen, K.; Klarqvist, M. Drug discovery today 2017, 22, 133–139.
- (4) Boland, S.; Bourin, A.; Alen, J.; Geraets, J.; Schroeders, P.; Castermans, K.; Kindt, N.; Boumans, N.; Panitti, L.; Fransen, S.; Vanormelingen, J.; Stassen, J. M.; Leysen, D.; Defert, O. J. Med. Chem. 2015, 58, 4309–4324.
- (5) Bhuniya, D.; Deshpanede, A.; Kandalkar, S.; Kobal, B.; Vyavahare, V.; Kaduskar, R. Patent US 2012214735A1, 2012
- (6) Lehmann-lintz, T.; Kley, J.; Redemann, N.; Sauer, A.; Thomas, L.; Wiedenmayer, D.; Austen, M.; Danilewicz, J.; Schneider, M.; Schreiter, K.; Black, P.; Blackaby, W.; Linney, I. Patent WO 2011104337, 2011
- (7) Barker, S. A.; Brimacombe, J. S.; Foster, A. B.; Whiffen, D. H.; Zweifel, G. *Tetrahedron* **1959**, *7*, 10–18.
- (8) (a) Avi, M.; Fechter, M. H.; Gruber, K.; Belaj, F.; Poechlauer, P.; Griengl, H. *Tetrahedron* 2004, 60, 10411–10418. (b) Lopfe, M.; Linden, A.; Heimgartner, H. *Heterocycles* 2011, 82, 1267–1282. (c) Yamaguchi, A.; Hiyoshi, N.; Sato, O.; Shirai, M. Top. *Catal.* 2010, 53, 487–491. (d) Matteson, D. S. *Science of Synthesis* 2004, 6, 5–79. (e) Chini, M.; Crotii, P.; Gardelli, C.; Macthia, F. *Tetrahedron* 1994, 50, 1261–174. (f) Mihailovic, M. L.; Marinkovic, D. *Croat. Chem. Acta.* 1986, 59, 109–120. (g) Mihailovic, M. L.; Pavlovic, N.; Gojkovic, S. *Glasnik Hemijskog Drustva Beograd* 1975, 40, 309–319. (h) Hartman, F. C.; Barker, R. J. Org. Chem. 1964, 29, 873–877.
- (9) Baldwin, J. J.; Claremom, D. A.; Tice, C. M.; Cacatian, S.; Dillard, L. W.; Ishchenko, A.V.; Yuan, J.; Xu, Z. R.; Mcgeehan, G; Zhao, W.; Simpson, R. D.; Singh, S. B.; Flaherty, P. T.; Patent WO 2008036216, **2008**
- (10) (a) Brown, H. C.; Gupta, A. K. J. Organomet. Chem. 1988, 341, 73–81.
 (b) Brown, H. C.; Prasad, J. V. N. V. J. Org. Chem. 1986, 51, 4526–4530.
 (c) Brown, H. C.; Bakshi, R. K.; Singaram, B. J. Am. Chem. Soc. 1988, 5, 1529–1534. (d) Brown, H. C.; Prasad, J. V. N. V. J. Am. Chem. Soc. 1986, 108, 2049–2054. (e) Brown, H. C.; Prasad, J. V. N. V. J.; Zee, S. H. J. Org. Chem. 1985, 50, 1582–1589. (f) Brown, H. C.; Joshi, N. N. J. Org. Chem. 1985, 4059–4062. (g) Narayana, C.; Periasamy, M. J. Chem. Soc., Chem. Commun. 1987, 24, 1857–1859.
- (11) Wu, M. H.; Hansen, K. B.; Jacobsen, E. N. Angew. Chem. Int. Ed. 1999, 38, 2012–2014.
- (12) Savage, S.; Babu, S.; Zak, M.; Mao, Z.; Cao, J.; Ge, Y.; Ma, D.; Jiang, G. Synlett 2013, 24, 987–990.
- (13) Rajendran, R.; Savita, G.; Nagabushanam, K.; Muhammed, M. *Tetrahedron: Asymmetry* **2013**, *24*, 663–668.
- (14) Shiro, Y.; Kato, K.; Fujii, M.; Ida, Y.; Akita, H.; *Tetrahedron* **2006**, *62*, 8687–8695.
- (15) Ashoorzadeh, A.; Archibald, G.; Caprio, V. Tetrahedron 2009, 65, 4671-4680.

NUSCRIPT ACCEPTED MA

Tetrahedron

Highlights

. (S)-3-hydroxytetrahydropyranwas synthesized

frominexpensive L-glutamic acid.

. One step intramolecular etherification was

promoted by Tf₂Ounder mild conditions.

Accepting . The product was prepared with >95% ee in a

gram-scale without recrystallization.

4